News

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss—up to 24% with ...
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...
There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...
These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.
Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly ...
Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...
In a statement on Monday, Amgen Inc. (NASDAQ:AMGN) announced that its phase 2 study of its weight loss drug candidate, MariTide, demonstrated up to 20 percent average weight loss in people living with ...